Ken Griffin
LFCR icon

Ken Griffin’s Lifecore Biomedical LFCR Stock Holding History

Ken Griffin’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.3K Buy
+10,300
New +$71.1K ﹤0.01% 12505
2024
Q3 		– Sell
-3,600
Closed -$18.5K – 14797
2024
Q2 		$18.5K Sell
3,600
-12,400
-78% -$73.4K ﹤0.01% 12713
2024
Q1 		$85K Buy
+16,000
New +$114K ﹤0.01% 11578
2023
Q4 		– Sell
-44,400
Closed -$335K – 14831
2023
Q3 		$335K Sell
44,400
-6,300
-12% -$57.6K ﹤0.01% 8940
2023
Q2 		$490K Buy
50,700
+46,100
+1,002% +$282K ﹤0.01% 7985
2023
Q1 		$17.4K Sell
4,600
-2,100
-31% -$11.7K ﹤0.01% 13159
2022
Q4 		$43.4K Buy
+6,700
New +$55.2K ﹤0.01% 12300
2022
Q1 		– Sell
-10,400
Closed -$115K – 14155
2021
Q4 		$115K Sell
10,400
-200
-2% -$1.94K ﹤0.01% 12575
2021
Q3 		$98K Sell
10,600
-12,300
-54% -$134K ﹤0.01% 12900
2021
Q2 		$258K Buy
22,900
+10,300
+82% +$119K ﹤0.01% 11629
2021
Q1 		$134K Buy
+12,600
New +$142K ﹤0.01% 12176

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ken Griffin's LFCR Position: Q1 2026 in Review

Ken Griffin sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 18,116 shares — an estimated $125K sold.

Ken Griffin first reported a position in LFCR in Q3 2013 and held it in 28 quarters. The position peaked at $695K in Q1 2014. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Ken Griffin reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 18,116 Lifecore Biomedical shares in Q1 2026, an estimated $125K.
  • Ken Griffin first reported a position in Lifecore Biomedical in Q3 2013 and held it in 28 quarters.
  • Ken Griffin's Lifecore Biomedical position peaked at $695K in Q1 2014.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.